Systemic immunoglobulin light-chain amyloidosis

Clinical Lymphoma and Myeloma

Volumn 7, Issue 3, 2006, Pages 182-185

  Comenzo, Raymond L ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Bortezomib; Lenalidomide; Plasma cells; Stem cell transplantation; Thalidomide

Indexed keywords

AMYLOID; BORTEZOMIB; CONGO RED; DEXAMETHASONE; IMMUNOGLOBULIN LIGHT CHAIN; LENALIDOMIDE; MELPHALAN; MONOCLONAL ANTIBODY; PREALBUMIN; PREDNISONE; THALIDOMIDE;

ADJUVANT THERAPY; AMYLOIDOSIS; AUTOLOGOUS STEM CELL TRANSPLANTATION; BRADYCARDIA; CLINICAL FEATURE; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DIFFERENTIAL DIAGNOSIS; DOSE RESPONSE; DRUG EFFICACY; ELECTRON MICROSCOPY; FAMILIAL AMYLOIDOSIS; FLUID RETENTION; FOLLOW UP; HIGH RISK PATIENT; HUMAN; LEUKEMIA; MONOCLONAL IMMUNOGLOBULINEMIA; MORTALITY; MYELODYSPLASIA; NEUROPATHY; OVERALL SURVIVAL; PROTEIN TARGETING; QT PROLONGATION; RISK ASSESSMENT; SHORT SURVEY; SIDE EFFECT; THROMBOEMBOLISM; TREATMENT RESPONSE;

EID: 37849185952     PISSN: 15579190     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2006.n.056     Document Type: Review

References (29)

1. Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med 2003; 349:583-596.
2. Falk RH. Diagnosis and management of the cardiac amyloidoses. Circulation 2005; 112:2047-2060.
3. Arbustini E, Verga L, Concardi M, et al. Electron and immuno-electron microscopy of abdominal fat identifies and characterizes amyloid fibrils in suspected cardiac amyloidosis. Amyloid 2002;9:108-114.
4. Lachmann HL, Booth DR, Booth SE, et al. Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis. N Engl J Med 2002; 346:1786-1791.
5. Comenzo RL, Zhou P, Fleisher M, et al. Seeking confidence in the diagnosis of systemic AL (Ig light-chain) amyloidosis: patients can have both monoclonal gammopathies and hereditary amyloid proteins. Blood 2006; 107:3489-3491.
6. Merlini G, Westermark P. The systemic amyloidoses: clearer understanding of the molecular mechanisms offers hope for more effective therapies. J Intern Med 2004; 255:159-178.
7. Bradwell A, Carr-Smith HD, Mead GP, et al. Highly sensitive automated immunoassay for immunoglobulin free light chains in serum and urine. Clin Chem 2001; 47:673-680.
8. Bradwell AR. Serum free light chain measurements move to center stage. Clin Chem 2005; 51:805-807.
9. Lachmann HJ, Gallimore R, Gillmore JD, et al. Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Br J Haematol 2003; 122:78-84.
10. Palladini G, Campana C, Klersy C, et al. Serum N-terminal pro-brain natriuretic pepticle is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation 2003; 107:2440-2445.
11. Dispenzieri A, Gertz MA, Kyle RA, et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol 2004; 22:3751-3757.
12. Dispenzieri A, Gertz MA, Kyle RA, et al. Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood 2004; 104:1881-1887.
13. Palladini G, Lavatelli F, Russo P, et al. Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL. Blood 2006; 107:3854-3858.
14. Gertz MA, Comenzo R, Falk RH, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis. Am J Hematol 2005; 79:319-328.
15. Palladini G, Perfetti V, Obici L, et al. Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. Blood 2004; 103:2936-2938.
16. Gertz MA, Kyle RA. Acute leukemia and cytogenetic abnormalities complicating melphalan treatment of primary systemic amyloidosis. Arch Intern Med 1990; 150:629-633.
17. Palladini G, Perfetti V, Perlini S, et al. The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL). Blood 2005; 105:2949-2951.
18. Gertz MA, Blood E, Vesole DH, et al. A multicenter phase 2 trial of stem cell transplantation for immunoglobulin light-chain amyloidosis (E4A97): an Eastern Cooperative Oncology Group study. Bone Marrow Transplant 2004; 34:149-154.
19. Sanchorawala V, Wright DG, Seldin DC, et al. High-dose intravenous melphalan and autologous stem cell transplantation as initial therapy or following two cycles of oral chemotherapy for the treatment of AL amyloidosis: results of a prospective randomized trial. Bone Marrow Transplant 2004; 33:381-388.
20. Comenzo RL, Gertz MA. Autologous stem cell transplantation for primary systemic amyloidosis. Blood 2002; 99:4276-4282.
21. Jaccard A, Moreau P, Leblond V, et al. Autologous stem cell transplantation (ASCT) versus oral melphalan and high-dose dexamethasone in patients with AL (primary) amyloidosis: results of the French Multicentric Randomized Trial (MAG and IFM Intergroup). Blood 2005; 106:127a (Abstract #421).
22. Dispenzieri A, Kyle RA, Lacy MQ, et al. Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study. Blood 2004; 103:3960-3963.
23. Seldin DC, Anderson JJ, Sanchorawala V, et al. Improvement in quality of life of patients with AL amyloidosis treated with high-dose melphalan and autologous stem cell transplantation. Blood 2004; 104:1888-1893.
24. Facon T, Mary JY, Harousseau J, et al. Superiority of melphalan and prednisone (MP) + thalidomide (THAL) over MP and autologous stem cell transplantation in the treatment of newly diagnosed elderly patients with multiple myeloma. J Clin Oncol 2006; 24(18 suppl): 1s (Abstract #1).
25. Mateos MV, Hernandez JM, Hernandez MT, et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study. Blood 2006; 108:2165-2172.
26. Cohen AD, Zhou P, Reich L, et al. Adjuvant dexamethasone (D) ± thalidomide (T) improves hematologic and organ responses after risk-adapted high-dose melphalan with autologous stem cell transplant (SCT) for patients with systemic AL amyloidosis (AL). Blood 2005; 106:340a (Abstract #1163).
27. Hrncic R, Wall J, Wolfenbarger DA, et al. AL amyloidosis. Antibody-mediated resolution of light chain-associated amyloid deposits. Am J Pathol 2000; 157:1239-1246.
28. Dispenzieri A, Lacy MQ, Zeldenrust SR, et al. Lenalidomide has activity in a phase II trial in patients with primary systemic amyloidosis. Blood 2005; 106:77a (Abstract #252).
29. Sanchorawala V, Wright DG, Rosenzweig M, et al. Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase II trial. Blood 2006 [Epub ahead of print].